LENVIMA® in combination with everolimus for the 2L treatment of advanced renal cell carcinoma.

Recommended dose and dose modifications1,a

Interrupt, reduce, and/or discontinue LENVIMA based on the type and/or severity (grade) of the adverse reaction

Recommended dose modifications for LENVIMA in advanced RCC Recommended dose modifications for LENVIMA in advanced RCC mobile

Capsules pictured are not actual size.

Review the full Prescribing Information for everolimus for recommended dose modifications1,c

Recommended dose modification for toxicities thought to be related to everolimus and LENVIMA + everolimus

Proactively plan to manage nausea, vomiting, or diarrhea with concomitant medications as necessary prior to interruption or dose reduction of LENVIMA.

  • In Study 205, ARs led to dose reductions and interruption in 89% of patients receiving LENVIMA + everolimus1
  • Treatment discontinuation due to ARs occurred in 29% of patients receiving LENVIMA + everolimus1

AR=adverse reaction.

  1. aReduce dose in succession based on the previous dose level (18 mg, 14 mg, 10 mg, or 8 mg per day).
  2. bRefers to the same or a different adverse reaction that requires dose modification.
  3. cRefer to everolimus Prescribing Information for additional dose modification information.

For the management of specific adverse reactions, please see the Adverse Reaction Management section below.


AR management

Help manage ARs with PI-guided strategies

Click on the bar of each AR for PI-guided strategies. For the complete list of ARs, see full Prescribing Information.

  • Decreased appetite

    Decreased appetite-colored icon Decreased appetite-white icon

    PI-guided strategies to help manage decreased appetite1

    PI-guided-strategies to manage decreased appetite when taking LENVIMA for advanced renal cell carcinoma
  • Decreased weight

    Decreased weight-colored icon Decreased weight-white icon

    PI-guided strategies to help manage decreased weight1

    PI-guided strategies to manage decreased weight when taking LENVIMA for advanced renal cell carcinoma

    CTCAE v4.0 does not define grade 4 decreased weight. Permanently discontinue for grade 4 adverse reactions.

  • Diarrhea

    Diarrhea-colored icon Diarrhea-white icon

    PI-guided strategies to help manage diarrhea1

    PI-guided-strategies to manage diarrhea when taking LENVIMA for advanced renal cell carcinoma

    Promptly initiate management of diarrhea. Withhold and resume at a reduced dose upon recovery, or permanently discontinue LENVIMA based on severity.1

  • Fatigue

    Fatigue-colored icon Fatigue-white icon

    PI-guided strategies to help manage fatigue1

    PI-guided-strategies to manage fatigue when taking LENVIMA for advanced renal cell carcinoma

    CTCAE v4.0 does not define grade 4 fatigue. Permanently discontinue for grade 4 adverse reactions.

  • Hypertension

    Hypertension-colored icon Hypertension-white icon

    PI-guided strategies to help manage hypertension1

    Control blood pressure prior to initiating treatment

    PI-guided-strategies to manage hypertension when taking LENVIMA for advanced renal cell carcinoma
  • Nausea

    Nausea-colored icon Nausea-white icon

    PI-guided strategies to help manage nausea1

    PI-guided strategies to manage nausea when taking LENVIMA for advanced renal cell carcinoma

    CTCAE v4.0 does not define grade 4 nausea. Permanently discontinue for grade 4 adverse reactions.

  • Proteinuria

    Proteinuria-colored icon Proteinuria-white icon

    PI-guided strategies to help manage proteinuria1

    PI-guided strategies to manage proteinuria when taking LENVIMA for advanced renal cell carcinoma

AR=adverse reaction; PI=Prescribing Information; CTCAE=Common Terminology Criteria for Adverse Events; BP=blood pressure.

Download LENVIMA Access and Reimbursement Brochure icon

Download the LENVIMA AR Management Guide